The Effect of Ticagrelor on 15-Epi-Lipoxin A4 and Inflammation
Status:
Withdrawn
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
Ticagrelor and clopidogrel are FDA-approved drugs for inhibition of platelet hyper-reactivity
in certain clinical situations. The platelet inhibition and patient outcomes (PLATO) trial
showed that in patients with acute coronary syndromes, ticagrelor significantly reduced the
primary endpoint (cardiovascular death, myocardial infarction or stroke), all-cause mortality
and cardiovascular mortality compared to clopidogrel. It has been suggested that in addition
to its anti-platelet effects, ticagrelor has additional unique effects, including
anti-inflammatory effects that are not shared by clopidogrel. In the present study the
investigators will assess whether ticagrelor, as compared to clopidogrel, increases serum
levels of 15-epi-lipoxin A4, a potent endogenous anti-inflammatory mediator.